EGFR and esophageal squamous cell carcinoma: Overall, our results contribute additional evidence to support investigation of EGFR inhibitors in EGFR CNG positive ESCC and suggest that a combination strategy with taxanes has the potential for synergism thereby optimising clinical impact and effectiveness.